Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) covering Russia and the Eurasian Economic Union
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, July 14, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement with Moscow-based pharmaceutical company JSC Lancet for the distribution of Basilea’s antibiotic Zevtera® (ceftobiprole medocaril) in Russia, as well as in the other countries of the Eurasian Economic Union.
Under the terms of the agreement, JSC Lancet is granted the exclusive right to register, distribute and commercialize Zevtera in the license territory, whilst Basilea will supply JSC Lancet with product at a transfer price. In addition, Basilea will receive an upfront payment and be eligible for sales milestone payments.
Regulatory filings by JSC Lancet will be based on the European regulatory dossier that led to approvals of Zevtera for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP). Zevtera is currently approved in 29 countries and marketed in 19.
David Veitch, Chief Executive Officer, stated: "We are pleased to extend our commercial partnerships for Zevtera to Russia and other Eurasian countries. JSC Lancet is a leading hospital products company and one of the fastest growing pharmaceutical companies in Russia. We look forward to JSC Lancet making Zevtera available to physicians and patients, who are in need of new treatment options for severe bacterial infections.”
About Zevtera (ceftobiprole medocaril)
Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp.1 The brand is currently approved and marketed as Zevtera and Mabelio in a number of countries in Europe and beyond. Basilea has entered into license and distribution agreements for the brand in Europe, Eurasian countries, Latin America, China, Canada, Israel, and the Middle East and North Africa (MENA) regions.
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
About JSC Lancet
JSC Lancet is one of the leaders of the hospital market in Russia. The company develops its business in strategic partnerships with leading manufacturers of innovative medical products. One of its key success factors is to provide comprehensive healthcare solutions, ranging from diagnostics and hospital-based treatments, to ensuring the availability of high-end medical products throughout the Eurasian Economic Union. http://lancetpharm.ru/en/
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
|Phone||+41 61 606 1102|
This ad hoc announcement can be downloaded from www.basilea.com.
- Summary of Product Characteristics (SmPC) Zevtera: https://www.medicines.org.uk/emc/product/9164/smpc
[Accessed: July 13, 2021]